The study, which was issued by
The new drug, lecanemab, is capable of reducing the "clinical decline on the global cognitive and functional scale, CDR-SB, compared with placebo at 18 months by 27%,"
The phase three study was carried out at various medical centers over 18 months, with 1,795 patients who were in the early stages of the disease and aged 50 to 90.
"Today's announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer's disease, and provide a clinically meaningful impact on cognition and function," said
Results from the clinical trial show that the monoclonal antibody present in lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in less cognitive decline than the placebo after 18 months.
The study also concluded that the drug was associated with adverse effects and that "longer trials are warranted to determine the efficacy and safety of lecanemab in early Alzheimer's disease."
© 2022 EFE News Services (U.S.) Inc., source